Hyperemesis in a Young Woman: Diagnosis

The IL-23 inhibitor is the only drug in the class available with both subcutaneous and intravenous administration options for treatment induction, according to J&J.

Recurrent C difficile requires pulse vancomycin therapy; fecal microbiota transplant shows promise.

The novel therapy combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.

Your daily dose of the clinical news you may have missed.

The INTERCEPT project aims to build a blood risk score that can identify individuals with a high risk of developing Crohn disease within 5 years of initial evaluation.